Vascular Biogenics Ltd (VBLT)

[wcopeland]

Try to think about this a bit more, Oren. It takes a TEAM to successfully get a drug to market, and it is not always easy to perceive and quantify one's value. Their backgrouns might be key to the regulatory and financial health of the company (and patients, and shareholders). What if Dr. Kelley leverages knowledge learned at MMRC to critically pitch the value of VB-111? Hastings has been with InCyte - which has long been discussed as a major acquisition target by the likes of Gilead, BMS, and Amgen. What if Hasting's has a connection that catalyzes a $10B buyout by Amgen? Would they still deserve to be fired? A great drug means nothing if it does not reach individuals in need.